20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Opus Genetics, Inc. - (IRD) operates in the NASDAQ industry and is headquartered in Durham, United States with about 27 employees. Its market capitalization is roughly $305 million. In the fiscal year ended 2025-12-31, IRD reported $14M in revenue and ($50M) in net income.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Interactive charts & full statements → Open the IRD valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $10M | $14M | $11M | $19M | $40M | $1M | $0M | — |
| Gross Profit | $10M | $14M | $11M | $19M | $40M | $1M | $0M | — |
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating Income (EBIT) | ($49M) | ($39M) | ($62M) | ($11M) | $18M | ($23M) | ($20M) | ($4M) |
| Operating Margin % | -490.0% | -271.9% | -564.7% | -55.5% | 45.7% | -3854.8% | — | — |
| Net Income | ($108M) | ($50M) | ($58M) | ($10M) | $18M | ($57M) | ($25M) | ($6M) |
| Net Margin % | -1080.0% | -349.3% | -523.4% | -52.4% | 44.9% | -9625.3% | — | — |
| EBITDA | ($105M) | ($48M) | ($58M) | ($10M) | $18M | ($57M) | ($18M) | ($5M) |
| Earnings Per Share (EPS) | $-0.64 | $-0.08 | $-2.15 | $-0.46 | $0.87 | $-3.82 | $-5.28 | $-0.87 |
| Shares Outstanding (M) | 111M | — | 27M | 22M | 21M | 15M | 5M | 7M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1M | $2M | $4M | $3M | $3M | $4M | $4M | $4M |
| Gross Profit | $1M | $2M | $4M | $3M | ($3M) | $4M | ($3M) | $4M |
| Gross Margin % | 100.0% | 99.4% | 100.0% | 100.0% | -108.9% | 100.0% | -80.8% | 100.0% |
| Operating Income (EBIT) | ($16M) | ($14M) | ($11M) | ($8M) | ($9M) | ($10M) | ($38M) | ($8M) |
| Operating Margin % | -2182.8% | -665.9% | -296.3% | -269.9% | -309.0% | -227.2% | -884.0% | -207.1% |
| Net Income | ($8M) | ($66M) | ($17M) | ($17M) | ($7M) | ($8M) | ($35M) | ($8M) |
| Net Margin % | -1072.6% | -3038.2% | -427.5% | -566.9% | -257.5% | -187.5% | -816.7% | -194.6% |
| EBITDA | ($8M) | ($65M) | ($15M) | ($17M) | ($7M) | ($7M) | ($10M) | ($8M) |
| Earnings Per Share (EPS) | $-0.07 | $-0.08 | $-0.24 | $-0.25 | $-0.12 | $-0.24 | $-1.11 | $-0.29 |
| Shares Outstanding (M) | 111M | 869M | — | 71M | 63M | 34M | 32M | 26M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($41M) | ($35M) | ($26M) | ($1M) | $14M | ($19M) | ($7M) | ($4M) |
| Capital Expenditures (CapEx) | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($41M) | ($35M) | ($26M) | ($1M) | $14M | ($19M) | ($7M) | ($4M) |
| FCF Margin % | -410.0% | -248.3% | -232.7% | -5.8% | 35.9% | -3288.6% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($12M) | ($13M) | ($10M) | ($6M) | ($10M) | ($9M) | ($7M) | ($5M) |
| Free Cash Flow (FCF) | ($12M) | ($13M) | ($10M) | ($6M) | ($10M) | ($9M) | ($7M) | ($5M) |
| FCF Margin % | -1582.8% | -590.0% | -254.4% | -200.0% | -356.3% | -205.8% | -172.9% | -132.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $93M | $50M | $37M | $54M | $49M | $26M | $18M | $2M |
| Cash & Cash Equivalents | $89M | $45M | $30M | $51M | $43M | $25M | $16M | $2M |
| Total Liabilities | $106M | $35M | $30M | $4M | $3M | $4M | $31M | $9M |
| Total Debt (Short + Long-Term) | $36M | $1M | $0M | $0M | $0M | $1M | $0M | $6M |
| Total Shareholders' Equity | ($13M) | $15M | $7M | $50M | $46M | $22M | ($13M) | ($8M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IRD viewer.
About TickerBase · Data methodology & sources · Privacy · Terms